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Abstract
Levels of caveolin-1 (Cav-1) in tumour epithelial cells increase during prostate cancer progression. Conversely,
Cav-1 expression in the stroma can decline in advanced and metastatic prostate cancer. In a large cohort of
724 prostate cancers, we observed significantly decreased levels of stromal Cav-1 in concordance with increased
Gleason score (p = 0.012). Importantly, reduced expression of Cav-1 in the stroma correlated with reduced
relapse-free survival (p = 0.009), suggesting a role for stromal Cav-1 in inhibiting advanced disease. Silencing
of Cav-1 by shRNA in WPMY-1 prostate fibroblasts resulted in up-regulation of Akt phosphorylation, and
significantly altered expression of genes involved in angiogenesis, invasion, and metastasis, including a> 2.5-fold
increase in TGF-β1 and γ-synuclein (SNCG) gene expression. Moreover, silencing of Cav-1 induced migration
of prostate cancer cells when stromal cells were used as attractants. Pharmacological inhibition of Akt caused
down-regulation of TGF-β1 and SNCG, suggesting that loss of Cav-1 in the stroma can influence Akt-mediated
signalling in the tumour microenvironment. Cav-1-depleted stromal cells exhibited increased levels of intracellular
cholesterol, a precursor for androgen biosynthesis, steroidogenic enzymes, and testosterone. These findings suggest
that loss of Cav-1 in the tumour microenvironment contributes to the metastatic behaviour of tumour cells by
a mechanism that involves up-regulation of TGF-β1 and SNCG through Akt activation. They also suggest that
intracrine production of androgens, a process relevant to castration resistance, may occur in the stroma.
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Introduction
The tumour microenvironment plays a crucial role in
the initiation and progression of prostate and other
cancers. It is now clear that cancer stroma promotes
increased microvessel density; recruits reactive stro-
mal fibroblasts, lymphocytes, and macrophages; and
releases peptide-signalling molecules and proteases
[1,2]. Cancer-associated fibroblasts (CAF) produce an
altered extracellular matrix (ECM), which can induce
epithelial–mesenchymal transition (EMT) or other
types of behaviours associated with a more aggressive
phenotype in neighbouring epithelial cells [3]. The
mechanisms by which the stromal cells adjacent to
the cancer epithelium undergo phenotypic alterations
and overproduce biologically active proteins, thereby
orchestrating stromal–epithelial crosstalk, are still
largely unresolved. However, a major role seems
to be played by the transforming growth factor β
(TGF-β) pathway [4,5]. The myofibroblastic ‘reactive’
phenotype of prostate cancer stromal cells is not fully
characterized, but the predominant cell population
expresses increased vimentin and fibroblast activation
protein (FAP), and decreased α-smooth muscle actin
(α-SMA), desmin, and calponin 1 (CNN1) [3,6].
Reactive prostate cancer stroma synthesizes collagen
type I [3] and expresses tenascin C (TNC) and TGF-β,
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which are involved in modulation of cell growth
and tumourigenesis [5]. However, the use of these
proteins as markers of prostate cancer progression is
controversial [3,6], and better parameters to define the
stroma of aggressive disease are needed.
Reduced levels of Cav-1 in the prostate stroma have
been reported [7–9]. A recent global gene expres-
sion analysis of prostate cancer stroma identified a
significant down-regulation of Cav-1 levels in grade
3 reactive stroma [6]. In line with this, and with
the association between reactive stroma and prostate
cancer progression [1], we recently reported that
loss of stromal Cav-1 correlates with the presence of
metastasis and is predictive of increased expression of
Cav-1 and active Akt, both of which are overexpressed
in advanced disease, in the tumour [9,10].
To elucidate the clinical significance of Cav-1 loss
in prostate cancer-associated stroma, we analysed a
unique tissue microarray (TMA) comprising specimens
from 724 patients with follow-up for biochemical
relapse [11]. In this large cohort, we observed
an inverse correlation of Cav-1 loss with relapse-
free survival. We also used immortalized prostatic
myofibroblasts as a model system to investigate the
molecular mechanism by which reduced expression of
Cav-1 influences tumour progression. We found that
when Cav-1 was silenced, the stromal gene expression
profile dramatically changed, with overexpression of
genes involved in metastasis and angiogenesis. Levels
of cholesterol, steroidogenic enzymes, and testosterone
were also increased. Furthermore, silencing of Cav-1 in
stromal cells induced tumour epithelial cell migration.
These results suggest that stromal Cav-1 is an impor-
tant mediator within the tumour microenvironment
that is protective against disease progression.
Materials and methods
Cav-1 expression in human tumours
Patient cohort enrolment and follow-up under the
Prostate SPORE data bank at the Baylor College of
Medicine, as well as pathological analysis of radical
prostatectomies for TMA construction, approved by
the Baylor College of Medicine Institutional Review
Board (YRB H-11436), have been described in detail
[11]. Clinical follow-up data included prostatic specific
antigen (PSA) relapse (defined as PSA > 0.4 ng or two
consecutive rises), clinical metastasis, and death. TMA
sections were immunostained with Cav-1 antibody
(Santa Cruz Biotechnology, Santa Cruz, CA, USA)
using an LSAB kit (DAKO, Carpinteria, CA, USA).
Immunoreactive staining of Cav-1 was analysed using
a 0–3+ scoring system for staining intensity and per-
centage of positive cells (labelling frequency) per field.
Reactive stroma
The tumour-specific stroma was defined as stroma
found in the invasive component of the cancer that was
not part of the normal pre-existing host stroma, graded
as reported previously [3], and analysed independently
of the epithelial grade of differentiation of the tumour.
Cell culture
LNCaP, DU145, PC3, WPMY-1, RWPE-1, and
RWPE-2 cells were from the American Type Culture
Collection (ATCC, Manassas, VA, USA).
RNA interference
For silencing of Cav-1 expression, WPMY-1 cells
were transfected with ON-TARGETplus SMARTpool
siRNA duplexes J-003467-06 Cav-1, or with control
siGENOME Non-Targeting siRNA #3 (Dharmacon
Inc, Lafayette, CO, USA) using LipofectamineTM
2000 (Invitrogen, Carlsbad, CA, USA), for 72 h. For
generation of cell lines with stable Cav-1 silencing,
WPMY-1 cells were infected with Cav-1 shRNA(h)
and shRNA(h2), or with control shRNA lentiviral
particles (Santa Cruz Biotechnology), in the presence
of Polybrene (Santa Cruz Biotechnology) [12], and
clones selected with puromycin 0.2 µg/ml (Invitrogen).
PCR array
Template cDNAs from WPMY-1 cells were character-
ized in technical triplicates using the Human Cancer
PathwayFinderTM RT2 ProfilerTM PCR Array and RT2
Real-Time SyBR Green/ROX PCR Mix (SA Bio-
sciences, Frederick, MD, USA). Real-time PCR was
performed on an ABI Prism StepOnePlus Sequence
Detector (Applied Biosystems, Foster City, CA, USA).
The resulting raw data were then analysed using the
web-based PCR Array Data Analysis Template (SA
Biosciences).
qRT-PCR
Total RNA from stable WPMY-1/shCAV-1 or
WPMY-1/shRNA cells was isolated, purified, and
reverse-transcribed as described elsewhere [13]. cDNA
was amplified using primers for tenascin-C (TNC);
calponin 1 (CNN1); glyceraldehyde-3-phosphate
dehydrogenase (GAPDH); angiopoietin 1 (ANGPT1);
TGF-β1 (TGFB1); contactin 1 (CNTN1); TEK tyro-
sine kinase, endothelial (TEK); γ-synuclein (SNCG);
thrombospondin 1 (THBS1); and seladin-1. Gene
expression of CYP17A1 was evaluated as previously
described [14]. The relative abundance of a given
transcript was estimated using the 2−Ct method,
following normalization to GAPDH.
Cholesterol and testosterone levels
Cholesterol content in WPMY-1/shCAV-1 or con-
trol was determined by gas chromatography–mass
spectrometry (GC–MS) [15,16]. In addition, a
Filipin-based detection kit (Cayman Chemical Com-
pany, Ann Arbor, MI, USA) was used to stain
intracellular cholesterol in full media (FM), serum-free
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media (SFM) or SFM + liposomes [17,18]. Cell
membranes were labelled with FITC-conjugated
cholera toxin B (CTxB) subunit (Sigma, St Louis,
MO, USA) [13,19]. Testosterone was determined
using a modified ID LC-MS/MS method [20].
Migration assay and proliferation assay
Cell migration of epithelial cells was performed using
conditioned medium from WPMY-1 cells infected
with shCav-1 or control shRNA [9,13]. WPMY-1 cell
proliferation was assessed using crystal violet (Sigma).
Co-culture assays and flow cytometry
For proliferation assays, we co-cultured WPMY-
1/shCAV-1 or WPMY-1/shRNA with LNCaP/GFP
cells (ratio 2 : 1) [21]. Stromal cells were pre-labelled
with CellTracker Red CPMTX (Invitrogen) [13].
After 48 h of co-culture, LNCaP cell proliferation
was assessed by counting GFP-positive cells in
20 randomly selected fields, in three independent
experiments [22]. To test the contribution of WPMY-
1-derived androgens to cancer cell proliferation,
WPMY-1 cells, treated with shCav-1 and exposed to
abiraterone acetate (10 µM) [23], were co-cultured with
LNCaP/GFP cells for 24 h. For cell cycle analysis,
Hoechst 33342 (5 µg/ml)-stained cells [24] were
quantified by flow cytometry using an Aria III Cell
Sorter (Becton-Dickson, San Jose´, CA, USA), and the
percentage of gated LNCaP/GFP cells in the G1/0, S,
and G2/M phases were analysed by FlowJo software
(Treestar), in three independent experiments.
Statistical analysis
Correlation of stromal Cav-1 with clinico-pathological
parameters and other markers was evaluated using
Spearman correlation coefficient testing. For survival
analysis, time to recurrence was defined as the interval
between the date of surgery and the date of iden-
tification of biochemical recurrence. Cox univariate
and multivariate proportional hazard models were used
to evaluate the predictive value of Cav-1 (original
score and dichotomized) for recurrence-free survival
and to determine the hazard ratios. Kaplan–Meier sur-
vival curves were constructed for patients with no and
detectable levels of Cav-1. The hazard ratio (HR) and
its 95% confidence interval (95% CI) were recorded
for each model. p values less than 0.05 were con-
sidered statistically significant. Evaluations were per-
formed using SPSS 16.0 software (SPSS Inc, Chicago,
IL, USA).
Results
Loss of stromal Cav-1 correlates with
clinico-pathological parameters and is predictive of
recurrence-free survival
We interrogated a TMA containing benign and
tumour prostate tissues from 724 patients, for which
histological and clinical parameters were available.
Cav-1 was strongly expressed in smooth muscle cells
and endothelial cells, as well as in the stroma surround-
ing the non-cancerous epithelial ducts (Figure 1A).
However, high-levels of Cav-1 in the reactive stroma
of prostate cancer were rare, being identifiable in only
3% of the samples. Stromal Cav-1 expression was
reduced in 17.3%, low in 35.4%, and completely lost in
44.5% of the tumours (Figure 1B). In association with
reduced Cav-1, we observed loss of PTEN, shown to
be a crucial alteration for malignant transformation in
the stroma of the mouse mammary gland [25,26], and
increased levels of NF-κB and Akt in epithelial cells
(Figure 1C). Levels of stromal Cav-1 were inversely
correlated with Gleason score (r2 = 0.93, p= 0.0124),
and clinical stage (r2 = 0.96, p= 0.0099), confirming
that expression of the protein declines substantially in
the stroma with tumour progression. Notably, poorly
differentiated tumours almost invariably exhibited a
loss or reduced expression of Cav-1 in the reactive
stroma. Recurrence-free survival was significantly
lower in patients with higher expression of Cav-1
[HR (95% CI) = 0.75 (0.61, 0.93), p= 0.009], which
is equivalent to a 33% increase in the estimated risk
of recurrence over the time of follow-up (Figure 1D).
A multivariate model, adjusting for clinical stage,
pre-operative PSA, extracapsular extension, tumour
margins, and Gleason grade, showed that loss of
Cav-1 in the stroma is not an independent prognostic
marker for disease progression (p= 0.0706). Detection
of stromal Cav-1 predicted a 54.5% increase in the
estimated risk of recurrence.
Cav-1 depletion in prostate stromal cells induces a
‘reactive stroma-like’ phenotype
In order to elucidate the mechanism by which loss
of stromal Cav-1 may play a role in disease progres-
sion, we used WPMY-1 immortalized benign prostatic
myofibroblasts [27]. WPMY-1 cells express Cav-1 at
high levels and release it into the medium (Figure 2A),
suggesting the interesting possibility that secreted stro-
mal Cav-1 might influence the biological behaviour
of epithelial cells. To investigate the functional sig-
nificance of Cav-1 loss in the prostate stroma, we
employed RNA interference. Transient silencing of
Cav-1 in WPMY-1 cells induced up-regulation of
tenascin C (TNC) and calponin 1 (CNN1), and down-
regulation of contactin 1 (CNTN1), markers of reac-
tive stroma [6,7]. In addition, we observed modest but
reproducible activation of Akt (Figure 2A).
Gene expression profile of Cav-1-deficient prostate
stromal cells reveals activation of oncogenic
pathways
Cav-1 was stably silenced in WPMY-1 cells using two
independent lentivirus-encoded shRNA constructs [12].
shCAV-1(h) induced more than 90% protein knock-
down in WPMY-1 populations (not shown). We then
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Figure 1. Loss of Cav-1 is predictive of disease-free survival. (A) Cav-1 immunostaining of prostate cancer sections showing high expression
of the protein in the stroma of normal prostate glands. Protein levels are dramatically decreased in the tumour stroma. (B) Cav-1 levels
are invariably low or absent in reactive stroma. (C) Cav-1 levels are directly correlated with PTEN levels and inversely correlated with Akt
and NF-κB levels. (D) Loss of Cav-1 is significantly associated with decreased disease-free survival (p= 0.0385).
generated several independent single cell clones, and
shCAV-1(h) # 13, which displayed nearly 90% down-
regulation of Cav-1, was selected for biochemical and
phenotypic analyses (Figure 2B). Akt activation was
confirmed in Cav-1 stable knockdown WPMY-1 cells,
as indicated by increased levels of p-Akt (S473), both
in full medium and in serum-starved conditions (Figure
2C), suggesting that the effect of Cav-1 on Akt activa-
tion is not influenced by soluble factors such as those
present in the serum.
We then employed the 84-gene Cancer Pathway
Finder PCR Array [28,29] to analyse the expression
profile of WPMY-1 cells in which Cav-1 had been
stably silenced. This array includes genes involved
in biological processes relevant to tumourigenesis and
cancer progression, such as cell cycle, adhesion, angio-
genesis, invasion, and metastasis (Figure 2D). Seven
genes exhibited at least a 2.5-fold change in expres-
sion in WPMY-1 cells in which Cav-1 was silenced
in comparison with cells infected with control shRNA
(Figure 2E), with two up-regulated and five down-
regulated genes. Four of these genes (TGF-β1, THBS1,
ANGPT1, and TEK) are involved in angiogenesis
[30–34]. Interestingly, levels of thrombospondin-1
(THBS1), an angiogenesis inhibitor [35], were down-
regulated in Cav-1-silenced cells, as were levels of
both the TEK receptor tyrosine kinase and its ligand
angiopoietin-1 (ANGPT1). Conversely, levels of TGF-
β1, known to promote angiogenesis and growth of can-
cer cells [4,32], and levels of the metastasis-associated
gene synuclein-γ (SNCG) were up-regulated in Cav-1-
knockdown cells. Levels of five of these genes were
investigated by qRT-PCR, which confirmed the results
of the array (Figure 2 F). Notably, we also observed
a 2.5-fold increase in COL18A1 levels, and a 2-fold
decrease of S100A4 levels in fibroblasts upon Cav-1
knockdown. Both genes have been linked to aggressive
cancer and metastasis [36,37].
Because several genes involved in angiogenesis were
influenced by Cav-1 knockdown, and to determine
whether this observation had biological consequences,
we measured the migration of mouse dermal endothe-
lial cells (MDECs), a standard in vitro angiogenesis
assay [38]. MDEC cell migration was 10% higher
when Cav-1-silenced WPMY-1 cells were used as
attractants in comparison with shRNA control cells
(Figure 3A). This result suggests that loss of stro-
mal Cav-1 might be involved in the establishment of a
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Figure 2. Cav-1 knockdown in WPMY-1 cells induces altered expression of genes involved in angiogenesis and oncogenesis. (A) WPMY-1
cell lysates and conditioned medium were blotted with Cav-1 antibody (top left). Cell lysates of WPMY-1 cells transfected with
Cav-1 siRNA and control siRNA were blotted with the indicated antibodies (top right). qRT-PCR analysis of WPMY-1 cells transfected with
Cav-1 siRNA and control siRNA, using primers for tenascin (TNC), calponin (CNN1), and contactin (CNTN1) (bottom left). Cell lysates of
WPMY-1 cells transfected with Cav-1 siRNA and control siRNA were blotted with the indicated antibodies (bottom right). (B) Cell lysates
of WPMY-1 cells transfected with control shRNA and different clones from two different Cav-1 shRNAs (h and h2) were blotted with the
indicated antibodies. (C) Cell lysates of WPMY-1 cells stably transfected with control shRNA and shCav-1 (h) #13 in full or serum-free
media were blotted with the indicated antibodies. (D) Heat map of a human Cancer PathwayFinder PCR Array after Cav-1 silencing in
WPMY-1 cells. (E) Expression of seven genes was significantly altered in Cav-1-silenced WPMY-1 cells in comparison with control cells.
(F) qRT-PCR analysis of WPMY-1 cells transfected with Cav-1 shRNA and control shRNA, using the indicated primers.
tumour microenvironment characterized by vasculoge-
nesis.
Cav-1 silencing in prostate stromal cells stimulates
proliferation and perturbs oncogenic cell signalling
Having observed increased levels of active Akt in Cav-
1 knockdown WPMY-1 cells (Figures 2A and 2C),
we asked whether activation of this signalling pathway
affected WPMY-1 cell proliferation. Consistent with
Akt activation, Cav-1 silencing resulted in increased
proliferation (Figure 3B and data not shown), down-
regulation of p53 and p21 (Figure 3C), and decreased
levels of cleaved PARP (Figure 3C), suggesting that
loss of Cav-1 confers pro-survival properties to stromal
cells. To demonstrate whether up-regulation of TGF-
β1 and SNCG in Cav-1-depleted stromal cells was
directly mediated by activation of the Akt pathway,
we inhibited Akt activation in Cav-1-silenced WPMY-
1 cells by a non-toxic dose (10 µM) of triciribine
(API-2) (Figure 3D). TGF-β1 and SNCG RNA levels
were both significantly down-regulated after 4 h of
treatment with API-2, and down-regulation of TGF-β1
was sustained after 8 h, suggesting that up-regulation
of these genes induced by Cav-1 silencing is mediated
by Akt signalling (Figure 3E).
Cav-1 silencing in WPMY-1 cells stimulates cancer
cell migration
Because Cav-1 loss in prostate cancer stroma in
vivo is associated with reactive stroma and metastatic
disease, and coincides with activation of oncogenic
signalling, we investigated whether Cav-1 loss in the
stroma influences the migratory abilities of cancer cells.
LNCaP, DU145, and PC3 cell migration was analysed
in response to WPMY-1 cells used as attractants
(Figure 4A) [13,39]. LNCaP cells did not migrate,
either in the absence or in the presence of WPMY-
1 cells, consistent with the poor metastatic potential
of this cell type [40]. Conversely, both DU145 and
PC3 cells exhibited increased migration in response to
the stromal cells. Interestingly, a stronger effect was
elicited from WPMY-1 cells on DU145 cells, whose
autonomous migration in the absence of stromal cells
was extremely low. Therefore, we used DU145 cells to
investigate the consequences of Cav-1 down-regulation
in WPMY-1 cells used as attractants for tumour cell
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Figure 3. Loss of Cav-1 in WPMY-1 potentiates the migration of endothelial cells. (A) Migration of mouse dermal endothelial cells (MDECs)
was significantly increased by Cav-1-depleted WPMY-1 cells. (B) Cell proliferation was assessed by using a crystal violet assay in WPMY-1
cells transfected with control siRNA or Cav-1 siRNA, showing increased proliferation in Cav-1-depleted stromal cells. (C) Cell lysates
from WPMY-1 cells transfected with Cav-1 siRNA and control siRNA were blotted with the indicated antibodies. (D) Cell lysates from
Cav-1-depleted WPMY-1 cells, treated with 10µM triciribine (API-2) for the indicated times, were blotted with the indicated antibodies.
(E) TGF-β1 and SNCG levels in Cav-1-depleted WPMY-1 cells treated with 10µM triciribine (API-2) were assayed by qRT-PCR.
migration. Cav-1 depletion in stromal cells induced
a 15% increase in DU145 cell migration, which was
significantly higher than the DU145 migration elicited
by parental stromal cells (Figure 4B), suggesting that
Cav-1 loss in the tumour stroma may influence tumour
cell migration. We also determined whether Cav-1 loss
in the stroma affected the migration of benign epithelial
cells, using tumourigenic RWPE-2 cells and their
isogenic non-tumourigenic counterpart, RWPE-1 cells
[41]. Interestingly, increased migration was observed
in the tumourigenic cell line as a consequence of
stromal Cav-1 knockdown, while the non-tumourigenic
epithelial cells were not affected by Cav-1 silencing in
stromal cells (Figure 4C).
Cav-1 knockdown in stromal cells leads to
increased intracellular cholesterol, steroidogenic
enzymes, and testosterone
Because Cav-1 binds to cholesterol and regulates the
intracellular transport of cholesterol to and from the
plasma membrane [42,43], and because of increas-
ing evidence of a role for cholesterol in prostate
cancer progression [44–46], we asked whether loss
of Cav-1 in stromal cells could alter cholesterol
levels and/or transport. Silencing of Cav-1 induced
an increase of intracellular cholesterol in stromal
cells, as shown semi-qualitatively by imaging (Figure
4D) and quantitatively by gas chromatography–mass
spectrometry (GC–MS) (Figure 4E). The effect
of Cav-1 depletion in increasing cholesterol levels
in fibroblasts was abolished when the cells were
cultured in serum-free medium (Figure 4D), and
treatment with cholesterol-rich liposomes reversed
this effect, increasing cholesterol levels in Cav-1-
silenced WPMY-1 cells but not control cells. Levels
of seladin-1, a key enzyme in cholesterol synthesis,
were reduced under the above conditions (Figure 4 F),
while the expression of proteins involved in sterol
metabolism and biosynthesis, including SREBP2 and
HSD3β1, was increased. FASN and AMPK, enzymes
that regulate fatty acid metabolism, were unaffected
(Figure 4G). Levels of StAR and 5-α-reductase type 1
(SRD5A1), key enzymes in the synthesis of steroids,
were increased in Cav-1-silenced stromal cells (not
shown). Importantly, mRNA levels of CYP17A1,
a cytochrome P450 enzyme implicated in de novo
androgen synthesis in castration-resistant prostate
cancer (CRPC) [47], were significantly higher in
Cav-1-silenced cells (Figure 4 F), suggesting that
Cav-1-deprived prostate stromal cells might synthe-
size androgens endogenously. Consistent with this
hypothesis, we observed increased testosterone pro-
duction and secretion in Cav-1-silenced stromal cells
(Figure 4H).
Proliferation of cancer cells induced by
Cav-1-depleted stromal cells is mediated by
testosterone
Co-culture experiments of LNCaP and WPMY-1
cells demonstrated that proliferation of the prostate
cancer epithelial cells was significantly induced by
Cav-1 silencing in stromal cells (Figures 5A and
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Figure 4. Functional consequences of Cav-1-silencing in WPMY-1 stromal cells. (A) LNCaP, DU145, and PC3 cell migration induced by
WPMY-1 cells, used in the bottom chamber as an attractant. The image depicts a heat map of a 24-well plate showing an increase in
CellTracker fluorescence (red) in migrating cells. (B) WPMY-1-induced DU145 cell migration, quantitatively analysed, was significantly
potentiated by depletion of Cav-1 in the migration-inducer stromal cells. (C) WPMY-1-induced migration of RWPE-2, but not RWPE-1,
cells was significantly potentiated by depletion of Cav-1 in the stromal cells. (D) Filipin staining of WPMY-1 cells transfected with Cav-1
siRNA and control siRNA cultured in full media (FM), serum-free media (SFM), and serum-free media supplemented with liposomes (SFM
+ liposomes). Intracellular cholesterol levels, which increased when Cav-1-depleted cells were cultured in FM or in the presence of
cholesterol-rich liposomes, were unchanged in the SFM condition. (E) Gas chromatography–mass spectrometry (GC–MS) of intracellular
cholesterol levels in Cav-1 siRNA and control siRNA cells showing a significant increase of intracellular cholesterol in Cav-1-depleted
cells. (F) qRT-PCR for seladin-1 and CYP17A1 in WPMY-1 cells transfected with Cav-1 shRNA and control shRNA. (G) Cell lysates from
WPMY-1 cells transfected with Cav-1 shRNA and control shRNA were blotted with the indicated antibodies. (H) Isotope dilution–liquid
chromatography–tandem mass spectrometry (ID–LC–MS/MS) of intracellular (left panel) and secreted (right panel) testosterone levels in
Cav-1 shRNA and control shRNA cells showing a significant increase of testosterone production in Cav-1-depleted cells.
5B), suggesting a potent stimulatory effect of loss of
stromal Cav-1 on the proliferation of cancer cells. We
then tested whether the excess of androgens detected
in Cav-1-depleted stromal cells was responsible for
the observed increased proliferation. Pharmacologi-
cal inhibition in stromal cells of CYP17A1, a crit-
ical enzyme in androgen synthesis, by abiraterone
acetate significantly suppressed the G2/M transition in
tumour cells (Figure 5C), suggesting that loss of stro-
mal Cav-1 promotes the proliferation of cancer cells
by stimulating androgen synthesis. In order to deter-
mine whether these findings reflect the clinical dis-
ease, we examined five RNA expression microarray
data sets from the Gene Expression Omnibus database
[48] for stromal expression of Cav-1 and CYP17A1
in prostate cancer. Among them, GSE6099 had no
CYP17A1 data (no probe) and in GSE11682 and
GSE25136 the percentage of stromal content was not
indicated. GSE8218 and GSE17951, with more than
50% stromal content, showed a significant negative
correlation between Cav-1 and CYP17A1 gene expres-
sion (p = 0.002, Figure 5D).
Discussion
We recently demonstrated that loss of Cav-1 in the
stroma correlates with high Gleason score and pres-
ence of metastasis [9], suggesting that down-regulation
of Cav-1 in prostatic stroma is clinically relevant.
Herein we investigated the clinical and functional sig-
nificance of stromal Cav-1 in prostate cancer using
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Figure 5. Proliferation of cancer cells induced by Cav-1-depleted stromal cells is mediated by testosterone. (A) Microphotographs of
LNCaP/GFP cells co-cultured with WPMY-1 cells treated with Cav-1 shRNA(h) or control shRNA, stained with CellTracker Red CPMTX
fluorescence dye, and quantified in B. (C) Flow cytometry analysis of LNCaP/GFP cells, co-cultured with Cav-1-silenced WPMY-1 with and
without pharmacological inhibition of CYP17A1. The plot shows the percentage of LNCaP/GFP cells in the G0/G1, S, and G2/M phases of
the cell cycle. Mean results of three independent experiments are shown± standard errors. (D) Scatter plot showing a significant inverse
correlation between Cav-1 and CYP17A1 gene expression in patients with more than 50% stromal content (p= 0.002).
the largest series of human prostate cancers ever
analysed for stromal Cav-1 in combination with an in
vitro model system. Our results show that the inverse
correlation between Cav-1 levels and Gleason score is
a reproducible feature of disease progression. Impor-
tantly, they indicate that loss of Cav-1 in the prostate
tumour microenvironment is indicative of reduced bio-
chemical relapse-free survival. This result is in agree-
ment with the finding that loss of stromal Cav-1 is clini-
cally relevant to breast cancer progression [49]. Intrigu-
ingly, our groups demonstrated that Cav-1 expression
in the prostate cancer epithelium increases with tumour
progression and that Cav-1 is a marker of metastatic
disease [9,45]. The inverse correlation between levels
of Cav-1 in the stroma and in the tumour suggests that
stromal Cav-1 functions to protect the host from the
malignant tumour. We also observed decreased levels
of PTEN and increased levels of NF-κB and Akt in
the tumour epithelium of specimens with low stromal
Cav-1 levels. Decreased PTEN expression and activa-
tion of the PI3K pathway have been associated with
increased risk of recurrence [50], and NF-κB is a major
oncogenic pathway, activated in prostate cancer metas-
tasis [51]. This is an important result that supports the
finding that reduced levels of stromal Cav-1 are asso-
ciated with features of advanced disease in the tumour
epithelium.
Functional studies presented here suggest that down-
regulation of stromal Cav-1 is likely to alter stro-
mal influences on tumour epithelium, tumour angio-
genesis, and cholesterol and androgen metabolism. In
order to determine the mechanisms by which loss
of Cav-1 in the stroma influences prostate cancer
progression, we used prostatic myofibroblasts, often
employed to study the relationship between cancer cells
and the tumour microenvironment [52]. Our results
indicate that Cav-1 down-regulation in the stroma,
which coincides with increased expression of the reac-
tive stroma marker TNC, induces a number of gene
alterations, including up-regulation of TGF-β1 and
SNCG, and down-regulation of THBS1, ANGPT1,
and TEK, suggesting a pro-angiogenesis effect. The
observed increase in endothelial cell migration, show-
ing that endothelial cells are attracted by Cav-1-
silenced stromal cells, confirms this result functionally.
We also show that Cav-1 silencing stimulates pro-
liferation and provokes oncogenic cell signalling in
prostate stromal cells, coincident with increased levels
of intracellular cholesterol and activation of steroido-
genic enzymes. These stromal alterations result in
increased tumour cell migration, demonstrating effects
on stromal–epithelial crosstalk.
Our observation of altered levels of TNC, CNN1,
and CNTN1 in Cav-1 knockdown cells is consistent
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with recent reports showing that Cav-1 down-
regulation occurs in reactive stroma [6,7]. While the
expression of other markers of reactive stroma was
not affected by Cav-1 knockdown, gene expression
profiling indicates that Cav-1-silenced stromal cells
undergo a number of additional alterations, including
overexpression of TGF-β1, an immunosuppressive
cytokine that plays a regulatory role in cell differen-
tiation by stimulating angiogenesis and inhibiting the
immune response to the tumour [53,54]. Several Cav-
1-dependent fibrotic phenotypes have been ascribed
to aberrant activation of the TGF-β pathway, which
is involved in prostate cancer progression [5,55].
In addition, Cav-1 has been proposed as a negative
regulator of TGF-β signalling [56]. However, ours
is the first report showing a significant increase of
TGF-β levels in myofibroblasts in response to Cav-1
knockdown. Our results support the hypothesis that
stromal cells lacking Cav-1 could be functionally
similar to cancer-associated fibroblasts (CAFs). This
hypothesis needs further investigation and would
benefit from tumour reconstitution studies.
Another gene significantly up-regulated in Cav-
1-silenced stromal cells was SNCG, a member of
the neuronal protein synuclein family, a protein
highly expressed in human cancers [57–60]. In
breast carcinoma, SNCG is often overexpressed as a
consequence of gene demethylation and is linked to
increased proliferation, metastasis, and drug resistance
[61–63]. SNCG expression can be also induced by
IGF-I through activation of MAPK and PI3K, and
SNCG knockdown results in decreased IGF-I-induced
activation of Akt [64]. Our results point for the first
time to increased SNCG in the prostate stroma through
Akt activation induced by Cav-1 loss and suggest that
the SNCG pro-survival role might involve activation
of paracrine signalling in the tumour microenviron-
ment. Given its primary role in neural tissue, SNCG
overexpression in the stroma might be involved
in cancer-related neurogenesis, a feature recently
associated with aggressive prostate cancer [65].
This study shows that loss of Cav-1 in myofi-
broblasts results in increased levels of intracellular
cholesterol, activation of steroidogenic enzymes, and
testosterone. The role of Cav-1 as a cholesterol trans-
porter is well known [43]. It has gradually emerged that
loss of Cav-1 in breast CAF results in oxidative stress,
which induces oxidative metabolism in adjacent cancer
cells, also known as the ‘reverse Warburg effect’ [66].
However, the finding of increased cholesterol levels in
prostate-derived myofibroblasts in response to Cav-1
loss is novel. Cholesterol is a precursor for androgenic
hormones; thus, our findings suggest that reactive
stroma may supply androgens to the epithelial tumour
cells under castrate conditions. Cav-1 loss increased
stromal levels of cholesterol and steroidogenic
enzymes, including CYP17A1, a rate-limiting enzyme
in androgen synthesis from cholesterol or other adrenal
precursors. Importantly, CYP17A1 has been suggested
as a mediator of cell-to-cell communication in the
tumour microenvironment and is secreted in human
serum exosomes [67], but this is the first study demon-
strating that CYP17A1 levels increase as a result of
Cav-1 loss. Our results favour the hypothesis that
one of the mechanisms by which abiraterone inhibits
intracrine production of androgens is by blocking the
function of CYP17A1 in the stroma. The sustained loss
of Cav-1 could be responsible, at least in part, for the
clinical resistance to androgen ablation in patients with
CRPC. We believe that this new finding has potentially
major clinical implications by suggesting that Cav-1
loss in the prostate stroma plays a role in mechanisms
of intracrine androgen metabolism in CRPC [68–70].
In summary, our findings indicate that Cav-1
loss in prostate cancer stroma coincides with more
aggressive disease in humans. Functional analysis of
prostate stromal cells in which Cav-1 was depleted
suggests that stromal Cav-1 may inhibit progression to
aggressive disease and that loss of the stromal protein
results in multiple effects on the tumour epithelia,
including resistance to hormone ablation.
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